

ORIGINAL ARTICLE

5-Nitroisatin-derived thiosemicarbazones: potential antileishmanial agents

Humayun Pervez¹, Nazia Manzoor¹, Muhammad Yaqub¹, and Khalid Mohammed Khan²

¹Institute of Chemical Sciences, Organic Chemistry Division, Bahauddin Zakariya University, Multan, Pakistan and ²H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan

Abstract

A series of 29 previously reported *N*⁴-substituted 5-nitroisatin-3-thiosemicarbazones **2–30** has been screened for leishmanicidal potential. Compounds **2–4**, **7**, **8**, **10–13**, **15–19**, **21**, **23**, **24**, **26**, **28** and **30** exhibited good to excellent antileishmanial activities with IC₅₀ values ranging from 0.44 ± 0.02 to 32.38 ± 0.66 µg/mL. Of these, **5**, **7**, **19** and **28** proved to be the most active antileishmanial agents, displaying activities with IC₅₀ values 1.78 ± 0.35, 0.44 ± 0.02, 1.91 ± 0.04 and 4.28 ± 0.75 µg/mL, respectively, which were even better than the standard drug, pentamidine (IC₅₀ = 5.09 ± 0.04 µg/mL). This study presents the first example of exhibition of leishmanicidal potential by isatin-thiosemicarbazones and as such furnishes a solid basis for further research on these compounds to develop more potent antileishmanial agents.

Keywords

Isatin-thiosemicarbazones, leishmanicidal activity, *Leishmania major*

History

Received 17 May 2013
Revised 15 August 2013
Accepted 16 August 2013
Published online 3 October 2013

Introduction

Leishmaniasis is a tropical disease caused by protozoa of the genus *Leishmania*. There are four different forms of the disease with a broad range of chemical manifestations. These include cutaneous leishmaniasis (CL), diffused cutaneous leishmaniasis (DCL), mucocutaneous leishmaniasis (MCL) and visceral leishmaniasis (VL). Of these, the last, being the most severe, causes almost 100% mortality, if untreated^{1,2}.

The available chemotherapy for leishmaniasis relies upon pentavalent antimonial (Sb^v) compounds, i.e. sodium stibogluconate (pentostam) or meglumine antimoniate (glucantime), which even though are still the first-line drugs, but are not totally safe and/or efficacious³. For the treatment of unresponsive cases, amphotericin B and pentamidine can be used, though they are not fully effective either and exhibit adverse side effects⁴. Miltefosine or hexadecylphosphocholine, an alkylphospholipid, originally developed as an anticancer agent, is the only oral antileishmanial drug found to be effective against both the CL⁵ and VL⁶, although causing serious gastrointestinal problems⁷. Furthermore, drug-resistant strains of *Leishmania* spp. have appeared, which necessitate the search for new, more effective and non- or least toxic chemotherapeutic agents.

Thiosemicarbazones are an important class of organic compounds, which possesses a number of medicinal properties, including antibacterial, antifungal, antiprotozoal, antitumoral, antiviral and more particularly, the antileishmanial activities^{8–21}. Isatin-derived thiosemicarbazones have also been found to possess a variety of biological activities, such as antimicrobial,

antineoplastic, antiplasmodial and antiviral^{22–34}. However, antileishmanial potential of this group of thiosemicarbazones has not been explored. Very recently, during random screening of the organic compounds prepared in our laboratory, we found that certain *N*⁴-substituted isatin-thiosemicarbazones bearing strong inductively electron-attracting substituents at position-5 of the isatin scaffold exhibited antileishmanial activity. This observation stimulated us to study the leishmanicidal properties of a series of 29 previously reported *N*⁴-alkyl/alkenyl/aryl substituted 5-nitroisatin-3-thiosemicarbazones^{35,36}, prepared by the condensation of 5-nitroisatin with appropriate thiosemicarbazides (Scheme 1). This paper, therefore, describes the *in vitro* leishmanicidal potential of these compounds. It also describes the effects of the nature of substituents attached to *N*⁴ of the thiosemicarbazone moiety on this very potential of the compounds. Further studies on such compounds with certain structural modifications are in progress.


Materials and methods

All reagents and solvents were used as obtained from the suppliers or recrystallized/redistilled as necessary. The 5-nitroisatin-3-thiosemicarbazones were prepared by treating 5-nitroisatin with appropriate thiosemicarbazides. The details of the reactions along with physical, analytical and spectral data of the compounds were reported elsewhere^{35,36}. *In vitro* leishmanicidal screening of the prepared compounds was made at Dr. Panjwani Center for Molecular Medicine and Drug Research, H.E.J. Research Institute of Chemistry, University of Karachi, Karachi, Pakistan.

In vitro antileishmanial activity

Leishmania major were grown in bulk in modified Novy-MacNeal-Nicolle (NNN) biphasic medium by using normal

Address for correspondence: Humayun Pervez, Institute of Chemical Sciences, Organic Chemistry Division, Bahauddin Zakariya University, Multan – 60800, Pakistan. Tel: +92 03007318346. Fax: +92 0619210068. E-mail: pdhpervaz@hotmail.com



Scheme 1. Synthesis of title compounds 2–30.

physiological saline. *Leishmania* promastigotes were cultured with Rosewell Park Memorial Institute (RPMI) 1640 medium, supplemented with 10% heat inactivated foetal bovine serum. Parasites at log phase were centrifuged at 2000 rpm for 10 min and washed three times with saline at the same speed and time. Parasites were diluted with fresh culture medium to a final density of 10^6 cells/mL.

In a 96-well microtiter plate, 180 μL of medium was added in first row and 100 μL of medium was added in other wells. A 20 μL of the experimental compound was added in medium and serially diluted. A 100 μL of parasite culture was in all wells and two rows were left for negative and positive controls. Negative controls

received only medium, whereas the positive control contained varying concentrations of standard leishmanicidal compound, pentamidine. The plate was incubated at 21–22 $^{\circ}\text{C}$ for 72 h. The culture was examined microscopically on an improved Neubauer counting chamber and IC_{50} values of compounds were calculated by Software Ezfit 5.03 (Perella Scientific, Amherst, NH). All assays were performed in triplicate.

Results and discussion

This study describes the *in vitro* determination of the leishmanicidal effects of 29 N^4 -substituted 5-nitroisatin-3-

Table 1. *In vitro* antileishmanial activity of compounds 2–30.

Compounds	IC ₅₀ ± SEM* (µg/mL)	Compounds	IC ₅₀ ± SEM* (µg/mL)
2	74.31 ± 0.69	17	12.94 ± 0.02
3	25.84 ± 0.205	18	13.00 ± 0.08
4	27.14 ± 0.06	19	1.91 ± 0.04
5	1.78 ± 0.35	20	51.20 ± 0.27
6	52.66 ± 0.28	21	26.95 ± 0.08
7	0.44 ± 0.02	22	63.89 ± 1.39
8	29.11 ± 0.70	23	25.93 ± 0.03
9	71.45 ± 0.61	24	25.86 ± 0.18
10	27.37 ± 1.05	25	53.65 ± 0.51
11	32.38 ± 0.66	26	26.79 ± 0.90
12	31.43 ± 0.18	27	82.12 ± 0.86
13	12.98 ± 0.145	28	4.28 ± 0.075
14	65.53 ± 1.14	29	>100
15	20.75 ± 0.01	30	15.58 ± 0.11
16	5.74 ± 0.01		
Pentamidine†	5.09 ± 0.04		

*Standard error of the mean.

†Standard drug for leishmanicidal activity.

thiosemicarbazones 2–30, the synthesis of which has been reported elsewhere^{35,36}.

In vitro antileishmanial activity

The synthetic thiosemicarbazones 2–30 were screened for their antileishmanial activity according to the literature protocol³⁷. Compound 2, i.e. 1-(5-nitro-2-oxindolin-3-ylidene)-4-phenylthiosemicarbazide served as a reference point to evaluate the effects of different substituents (alkyl, alkenyl and aryl bearing one or two functions about the phenyl ring) attached to *N*⁴ of the thiosemicarbazone moiety on the leishmanicidal potential of these compounds. All the compounds except 29 were found to be active against *Leishmania major*, showing varied leishmanicidal activity (IC₅₀ = 0.44 ± 0.02–82.12 ± 0.86 µg/mL) (Table 1). Compounds 3 and 4 having *n*-hexyl and allyl substituents at *N*⁴ of the thiosemicarbazone moiety were found to exhibit good antileishmanial activity (IC₅₀ = 25.84 ± 0.205 and 27.14 ± 0.06 µg/mL, respectively), whereas 2 bearing phenyl group at the same position displayed weak activity (IC₅₀ = 74.31 ± 0.69 µg/mL). Amongst the aryl-substituted compounds 5–7 possessing methyl substituents at different positions of the phenyl ring, the *ortho*-substituted compound 5 exhibited significant activity with an IC₅₀ value of 1.78 ± 0.35 µg/mL, while the *para*-substituted compound 7 displayed excellent leishmanicidal effect (IC₅₀ = 0.44 ± 0.02 µg/mL); however, the *meta*-substituted isomer 6 showed moderate activity (IC₅₀ = 52.66 ± 0.28 µg/mL). To the contrary, amongst the ethyl-substituted compounds 8 and 9, the *para*-substituted compound 9 was found to demonstrate weak leishmanicidal activity (IC₅₀ = 71.45 ± 0.61 µg/mL), when compared with the *ortho*-substituted compound 8, which displayed good activity (IC₅₀ = 29.11 ± 0.70 µg/mL). However, all the three methoxy-substituted compounds 10–12, regardless of the positions of substituents about the phenyl ring, exhibited good activity with IC₅₀ values 27.37 ± 1.05, 32.38 ± 0.66 and 31.43 ± 0.18 µg/mL, respectively. In the cases of trifluoromethyl-substituted compounds 13–15, the *ortho*- and *para*-substituted compounds 13 and 15 were found to show significant activity (IC₅₀ = 12.98 ± 0.145 and 20.75 ± 0.01 µg/mL, respectively), when compared with the *meta*-substituted compound 14, which exhibited weak activity (IC₅₀ = 65.53 ± 1.14 µg/mL). On the contrary, all the three monofluoro-substituted compounds 17–19 demonstrated significant activity with IC₅₀ values ranging from 1.91 ± 0.04 to 13.00 ± 0.08 µg/mL. Of these, the *para*-substituted compound

19 showed much pronounced activity with an IC₅₀ value of 1.91 ± 0.04 µg/mL. It is pertinent to mention that compound 16, the only trifluoromethoxy derivative (*para*-substituted) tested in the assay, showed leishmanicidal activity comparable with that of the standard drug, pentamidine (IC₅₀ = 5.74 ± 0.01 versus 5.09 ± 0.04 µg/mL). Amongst the two bromo-substituted compounds 20 and 21, the latter having a *para* substituent displayed good antileishmanial activity with an IC₅₀ value of 26.95 ± 0.08 µg/mL, whereas the former with an *ortho* substituent exhibited moderate activity (IC₅₀ = 51.20 ± 0.27 µg/mL). In contrast, amongst the two iodo-substituted compounds 22 and 23, compound 23 possessing a *para* substituent showed significant leishmanicidal effect (IC₅₀ = 25.93 ± 0.03 µg/mL), while the *ortho*-substituted compound 22 demonstrated weak activity (IC₅₀ = 63.89 ± 1.39 µg/mL). Interestingly, compound 24, the only cyano derivative (*meta*-substituted) tested in the assay, was found to exhibit significant activity (IC₅₀ = 25.86 ± 0.18 µg/mL), when compared with the corresponding trifluoromethyl derivative 14, which demonstrated weak leishmanicidal influence (IC₅₀ = 65.53 ± 1.14 µg/mL). Of the remainder active *N*⁴-aryl-substituted compounds 25–28 and 30, compound 25 having methoxy substituents at *ortho*, *para* (2,4) positions of the phenyl ring displayed moderate antileishmanial activity (IC₅₀ = 53.65 ± 0.51 µg/mL), whereas 26 with the same functions at *ortho*, *meta* (2,5) positions exhibited good activity (IC₅₀ = 26.79 ± 0.90 µg/mL). This shows that in the case of 25, substitution of additional methoxy substituent at *para* position of the phenyl ring caused significant reduction in activity, as the respective *ortho*-substituted compound 10 gave an IC₅₀ value of 27.37 ± 1.05 µg/mL in this assay. However, such an additional substitution at *meta* position of the phenyl ring was not found to cause any considerable change in the activity of compound 26 (IC₅₀ = 27.37 ± 1.05 versus 26.79 ± 0.90 µg/mL). More interestingly, in compound 28, substitution of additional fluoro function at *meta* position of the phenyl ring caused pronounced enhancement in the leishmanicidal activity (IC₅₀ = 4.28 ± 0.075 µg/mL), as the respective *ortho*-substituted compound 17 gave an IC₅₀ value of 12.94 ± 0.02 µg/mL in the present assay. Furthermore, as in compound 25, such an additional substitution of fluoro group at *para* position of the phenyl ring of compound 27 resulted into a decrement in its activity but to a level of much higher degree (IC₅₀ 12.94 ± 0.02 µg/mL → 82.12 ± 0.86 µg/mL). Compound 27 thus proved to be the least active derivative in the present series. Compound 30, the only dichloro derivative (*ortho*, *para*-substituted) tested in this assay, demonstrated significant activity (IC₅₀ = 15.58 ± 0.11 µg/mL). These structure–activity relationships (SARs) may serve as a basis for structural modifications aimed at the development of certain leishmanicidal agents of medicinal interest/importance.

The exact mechanism of antileishmanial activity displayed by the test thiosemicarbazones 2–30 is not known. However, it is generally accepted that the mode of leishmanicidal action of this class of agents involves primarily the inhibition of cysteine proteases found in different *Leishmania* species. Such an enzymatic inhibition may be attributed to nucleophilic addition of the active site cysteine thiol to the thiocarbonyl function of the thiosemicarbazone moiety, as recently proposed for cruzain, the related major parasitic cysteine protease from *Trypanosoma cruzi*^{10,12,29}. The antileishmanial activity shown by our test compounds 2–30 may also be attributed to inhibition of the ribonucleoside diphosphate reductase (RDR), an iron (Fe)-dependent enzyme catalyzing the rate-limiting step of DNA synthesis in the parasite. Notably, it is the ability of these compounds to act as tridentate metal chelators that leads to their leishmanicidal activity. The chelation of Fe from intracellular Fe pools results in the inhibition of RDR. The tridentate chelating

thiosemicarbazones have been proposed to act by inhibiting RDR^{13,38–40}. Such compounds have also been proposed to act by inhibiting dihydrofolate reductase^{41,42}.

It is only very recently that the thiosemicarbazone-metal complex, i.e. benzaldehyde thiosemicarbazone derived from limonene complexed with copper, termed as BenzCo, has been found to exhibit leishmanicidal activity against the promastigote, axenic amastigote and intracellular amastigote forms of *Leishmania amazonensis*. This leishmanicidal effect demonstrated by BenzCo was associated with the production of reactive oxygen species (ROS) leading to mitochondrial dysfunction, ultimately causing parasite death⁴³.

ROS may lead to oxidative damage of virtually any biomolecule. Mitochondria are particularly susceptible to such a damage caused by ROS that are continuously generated by the mitochondrial respiratory chain⁴⁴. The generation of ROS can also be induced by certain drugs, affecting parasite mitochondrial functions^{45–48}. The same principle worked for BenzCo in killing parasites. The treatment of parasites with BenzCo dose-dependently generated ROS and enhanced mitochondrial membrane lipid peroxidation, resulting in irreversible loss of mitochondrial functions such as mitochondrial respiration, oxidative phosphorylation and ion transport⁴⁴.

Conclusions

Conclusively, we have demonstrated the potential of *N*⁴-substituted 5-nitroisatin-3-thiosemicarbazones to exhibit antileishmanial activity. To the best of our knowledge, such a group of compounds has been scarcely studied previously for this activity. All the compounds of the present series except **29** were found to be active in the leishmanicidal assay. Of the active compounds, **20**, i.e. **2–4, 7, 8, 10–13, 15–19, 21, 23, 24, 26, 28** and **30** displayed good to excellent antileishmanial activity. Compounds **5, 7, 19** and **28** proved to be potent antileishmanial agents, showing leishmanicidal activity even better than the standard drug, pentamidine. These compounds may represent valid leads for further studies aimed at the development of efficacious antileishmanial compounds of medicinal interest. The SAR studies revealed that the antileishmanial potential of the trial compounds depended mainly on the electronic effects of the substituents attached to *N*⁴ of the thiosemicarbazone moiety. Nevertheless, extensive studies are required to determine the mechanism by which these compounds exhibit the leishmanicidal activity.

Declaration of interest

We acknowledge partial funding of this research work and the award of Indigenous PhD scholarship to NM by Higher Education Commission, Pakistan.

References

1. Tropical disease research. Progress 1999–2000. Geneva: World Health Organisation; 2001. Available from: <http://www.who.int/tdr/publications/documents/progress-99-00.pdf> [last accessed 12 Sep 2013].
2. Oliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. *Parasitol Today* 1993;9:323–8.
3. Rath S, Trivelin LA, Imbrunio TR, et al. Antimoniasis empregados no tratamento da leishmaniose: Estado da arte. *Quim Nova* 2003;26:550–5.
4. McGregor A. WHO warns of epidemic leishmania. *The Lancet* 1998;351:575.
5. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. *Clin Infect Dis* 2004;38:1266–72.
6. Prasad R, Kumar R, Jaiswal BP, et al. Miltefosine: an oral drug for visceral leishmaniasis. *Indian J Pediatr* 2004;71:143–4.
7. Sangraula H, Sharma KK, Rijal S, et al. Orally effective drugs for Kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. *J Assoc Physicians India* 2003;51:686–90.
8. Dodd RH, Ouannès C, Robert-Gèro M, et al. Hybrid molecules: growth inhibition of *Leishmania donovani* promastigotes by thiosemicarbazones of 3-carboxy- β -carboline. *J Med Chem* 1989;32:1272–6.
9. Bharti N, Husain K, Garza MTG, et al. Synthesis and in vitro antiprotozoal activity of 5-nitrothiophene-2-carboxaldehyde thiosemicarbazone derivatives. *Bioorg Med Chem Lett* 2002;12:3475–8.
10. Du X, Guo C, Hansell E, et al. Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. *J Med Chem* 2002;45:2695–707.
11. Beraldo H, Gambino D. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. *Mini-Rev Med Chem* 2004;4:31–9 and references therein.
12. Aguirre G, Boiani L, Cerecetto H, et al. In vitro activity and mechanism of action against the protozoan parasite *Trypanosoma cruzi* of 5-nitrofuryl containing thiosemicarbazones. *Bioorg Med Chem* 2004;12:4885–93.
13. Greenbaum DC, Mackey Z, Hansell E, et al. Synthesis and structure-activity relationships of parasitocidal thiosemicarbazone cysteine protease inhibitors against *Plasmodium falciparum*, *Trypanosoma brucei* and *Trypanosoma cruzi*. *J Med Chem* 2004;47:3212–19.
14. Husain K, Bhat AR, Azam A. New Pd(II) complexes of the synthesized 1-*N*-substituted thiosemicarbazones of 3-indole carboxaldehyde: characterization and anti-moebic assessment against *E. histolytica*. *Eur J Med Chem* 2008;43:2016–28.
15. Kandemirli F, Saracoglu M, Cavusoglu I, et al. Structure-activity relationship study by ETM method on potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. *Phil Nat* 2009;1:179–93.
16. Sharma K, Sing R, Fahmi N, et al. Microwave assisted synthesis, characterization and biological evaluation of palladium and platinum complexes with azomethines. *Spectrochim Acta A* 2010;75:422–7.
17. Glinma B, Kpoviessi SDS, Fatondji RH, et al. Synthesis, characterization and anti-trypanosomal activity of R-(α)-carvone and arylketones-thiosemicarbazones and toxicity against *Artemia salina* Leach. *J App Pharm Sci* 2011;8:65–70.
18. Sakirigui A, Kpoviessi SDS, Gbaguidi F, et al. Selective trypanocidal activity of some substituted thiosemicarbazones of citral from benin *Cymbopogon citratus* essential oil and their toxicity against *Artemia salina* Leach. *IJRRAS* 2012;12:454–62.
19. Demoro B, Sarniguet C, Sanchez-Delgado R, et al. New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents. *Dalton Trans* 2012;41:1534–43.
20. Navarro M, Gabbiani C, Messori L, et al. Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. *Drug Discov Today* 2010;15:1070–8.
21. Fatondji HR, Kpoviessi S, Gbaguidi F, et al. Structure-activity relationship study of thiosemicarbazones on an African trypanosome: *Trypanosoma brucei brucei*. *Med Chem Res* 2013;22:2151–62.
22. da Silva JFM, Garden SJ, Pinto AC. The chemistry of isatins: a review from 1975 to 1999. *J Braz Chem Soc* 2001;12:273–324 and references therein.
23. Pandeya SN, Smitha S, Jyoti M, et al. Biological activities of isatin and its derivatives. *Acta Pharm* 2005;55:27–46 and references therein.
24. Vine KL, Matesic L, Locke JM, et al. Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000–2008. *Anti-Cancer Agents Med Chem* 2009;9:397–414 and references therein.
25. Aboul-Fadl T, Bin-Jubair FAS. Anti-tubercular activity of isatin derivatives. *Int J Res Pharm Sci* 2010;1:113–26 and references therein.
26. Chiyanzu I, Hansell E, Gut J, et al. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. *Bioorg Med Chem Lett* 2003;13:3527–30.
27. Chiyanzu I, Clarkson C, Smith PJ, et al. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. *Bioorg Med Chem* 2005;13:3249–61.

28. Bal TR, Anand B, Yogeeswari P, et al. Synthesis and evaluation of anti-HIV activity of isatin β -thiosemicarbazone derivatives. *Bioorg Med Chem Lett* 2005;15:4451–5.
29. Chibale K. Economic drug discovery and rational medicinal chemistry for tropical diseases. *Pure Appl Chem* 2005;77: 1957–64.
30. Pirrung MC, Pansare SV, Sarma KD, et al. Combinatorial optimization of isatin- β -thiosemicarbazones as anti-poxvirus agents. *J Med Chem* 2005;48:3045–50.
31. Terzioğlu N, Karali N, Gursay A, et al. Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives. *Arkivoc* 2006(i):109–18.
32. Quenelle DC, Keith KA, Kern ER. In vitro and in vivo evaluation of isatin- β -thiosemicarbazone and marboran against vaccinia and cowpox virus infections. *Antivir Res* 2006;71:24–30.
33. Hall MD, Salam NK, Hellawell JL, et al. Synthesis, activity, and pharmacophore development for isatin- β -thiosemicarbazones with selective activity toward multidrug-resistant cells. *J Med Chem* 2009;52:3191–204.
34. Ermut G, Karali N, Cetin I, et al. Synthesis and chemotherapeutic activities of 5-chloro-1*H*-indole-2,3-dione 3-thiosemicarbazones. *Marmara Pharm J* 2013;17:147–54.
35. Pervez H, Manzoor N, Yaqub M, et al. Synthesis and urease inhibitory properties of some new N^4 -substituted 5-nitroisatin-3-thiosemicarbazones. *Lett Drug Des Discov* 2010;7:102–8.
36. Pervez H, Manzoor N, Yaqub M, et al. Synthesis and biological evaluation of some N^4 -substituted 5-nitroisatin-3-thiosemicarbazones. *Med Chem Res* 2012;21:2251–62.
37. Atta-ur-Rahman, Choudhary MI, Thomsen WJ. Bioassay techniques for drug development. The Netherlands: Harwood Academic Publishers; 2001:60–4.
38. Finch RA, Liu M-C, Grill SP, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. *Biochem Pharmacol* 2000;59:983–91.
39. Li J, Zheng LM, King I, et al. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarbazone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. *Curr Med Chem* 2001;8:121–33.
40. Danuta SK, Patricia Q, Richardson DR. Thiosemicarbazones: the new wave in cancer treatment. *Future Med Chem* 2009;1:1143–51 and references therein.
41. Lebrun E, Tu YX, van Rapenbusch R, et al. Inhibition of bovine dihydrofolate reductase and enhancement of methotrexate sensitivity by N^4 -(2-acetoxyethoxymethyl)-2-acetylpyridine thiosemicarbazone. *Biochim Biophys Acta* 1990;1034:81–5.
42. Choi I-H, Kim C. Flexible docking of an acetoxyethoxymethyl derivative of thiosemicarbazone into three different species of dihydrofolate reductase. *Arch Pharm Res* 2002;25:807–16.
43. Britta EA, Silva APB, Ueda-Nakamura T, et al. Benzaldehyde thiosemicarbazone derived from limonene complexed with copper induced mitochondrial dysfunction in *Leishmania amazonensis*. *PLoS One* 2012;7:e41440. doi:10.1371/journal.pone.0041440.
44. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. *Free Radical Bio Med* 1999;26: 463–71 and references therein.
45. Das R, Roy A, Dutta N, Majumder HK. Reactive organic species and imbalance of calcium homeostasis contributes to curcumin induced programmed cell death in *Leishmania donovani*. *Apoptosis* 2008;13: 867–82.
46. Roy A, Ganguly A, BoseDasgupta S, et al. Mitochondria-dependent reactive oxygen species-mediated programmed cell death induced by 3,3'-diindolylmethane through inhibition of FOF1-ATP synthase in unicellular protozoan parasite *Leishmania donovani*. *Mol Pharmacol* 2008;74:1292–307.
47. Pelizzaro-Rocha KJ, Veiga-Santos P, Lazarin-Bidoia D, et al. Trypanocidal action of eupomatenoid-5 is related to mitochondrion dysfunction and oxidative damage in *Trypanosoma cruzi*. *Microbes Infect* 2011;13:1018–24.
48. Fonseca-Silva F, Inacio JDF, Canto-Cavaleiro MM, et al. Reactive oxygen species production and mitochondrial dysfunction contribute to quercetin induced death in *Leishmania amazonensis*. *PLoS One* 2011;6:e14666. doi:10.1371/journal.pone.0014666.